H3-3B

Across TCGA pan-cancer cohorts, H3-3B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated H3-3B data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher H3-3B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H3-3B expression acts as an unfavorable survival marker.

LUAD, MESO, and CHOL are the cancer types where H3-3B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.337	0.837	<.001	18	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUSC	OS	Median	II,III,IV	0.279	0.732	.038	3	view →
SKCM	DFS	Median	II,III,IV	0.100	0.235	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

H3-3B–LUAD (OS)

Open the LUAD breakdown →